Skip to main navigation

Corporate Menu & Investor Relations

Contact Patients

Mission Leadership Community

The TCR Complex Therapeutic Approach TRuC-T Advantages Manufacturing Publications

Overview TC-210 TC-110 Pipeline

Press Releases In the News Awards

Overview Events Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage FAQs

Careers

Corporate Menu & Investor Relations

About Us Mission Leadership Community Technology The TCR Complex Therapeutic Approach TRuC-T Advantages Manufacturing Publications Programs Overview TC-210 TC-110 Pipeline News Press Releases In the News Awards Investors Overview Events Presentations Corporate Governance SEC Filings Stock Information Analyst Coverage FAQs Careers Careers Contact Patients

Press Releases

Latest Press Releases | In The News

Press Releases

Year

All News | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Jan 19, 2021

TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock

Jan 19, 2021

TCR² Therapeutics Announces Proposed Public Offering of Common Stock

Jan 08, 2021

TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones

Tools

Print Page
RSS Feeds
Email Alerts
Contact IR

100 Binney Street, Suite 710
Cambridge, MA 02142
617.949.5200

Corporate Menu & Investor Relations

About Us
Technology
Programs
News
Investors
Careers
Contact
Patients